Psoriasis in children and adolescents

Psoriasis is nowadays regarded as a multifactorial, inflammatory, immune-mediated systemic condition with predominant involvement of the skin. It starts in about one third of cases in childhood and adolescence and is often accompanied by marked impairment of the quality of life of sufferers and thei...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Monatsschrift Kinderheilkunde 2023, Vol.171 (5), p.420
Hauptverfasser: Hamm, Henning, Höger, Peter H
Format: Artikel
Sprache:ger
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page 420
container_title Monatsschrift Kinderheilkunde
container_volume 171
creator Hamm, Henning
Höger, Peter H
description Psoriasis is nowadays regarded as a multifactorial, inflammatory, immune-mediated systemic condition with predominant involvement of the skin. It starts in about one third of cases in childhood and adolescence and is often accompanied by marked impairment of the quality of life of sufferers and their parents. Aside from genetic disposition, trigger factors such as streptococcal infections are notably involved in manifestation and in exacerbations. The harmful role of comorbidities even in the young, particularly of obesity, has been well documented. Treatment options have considerably improved following the approval of five biologic agents in childhood but are still insufficiently used. The present article gives a short overview of current knowledge and the recommendations of the updated German guideline. Besides frequent types, unusual presentations such as pustular psoriasis, psoriasis dermatitis, and paradoxical psoriasis induced by tumor necrosis factor alpha (TNF-α) inhibitors are addressed.
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_37143470</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37143470</sourcerecordid><originalsourceid>FETCH-pubmed_primary_371434703</originalsourceid><addsrcrecordid>eNpjYeA0MDAy07U0srTgYOAqLs4yMDAwNDEyZGfgMDY3NDE2MTfgZFANKM4vykwszixWyMxTSM7IzEkpSs1TSMxLUUhMyc9JLU5OzSsp5mFgTUvMKU7lhdLcDHJuriHOHroFpUm5qSnxBUWZuYlFlfEwc40JKgAA1Kcsbw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Psoriasis in children and adolescents</title><source>SpringerLink Journals - AutoHoldings</source><creator>Hamm, Henning ; Höger, Peter H</creator><creatorcontrib>Hamm, Henning ; Höger, Peter H</creatorcontrib><description>Psoriasis is nowadays regarded as a multifactorial, inflammatory, immune-mediated systemic condition with predominant involvement of the skin. It starts in about one third of cases in childhood and adolescence and is often accompanied by marked impairment of the quality of life of sufferers and their parents. Aside from genetic disposition, trigger factors such as streptococcal infections are notably involved in manifestation and in exacerbations. The harmful role of comorbidities even in the young, particularly of obesity, has been well documented. Treatment options have considerably improved following the approval of five biologic agents in childhood but are still insufficiently used. The present article gives a short overview of current knowledge and the recommendations of the updated German guideline. Besides frequent types, unusual presentations such as pustular psoriasis, psoriasis dermatitis, and paradoxical psoriasis induced by tumor necrosis factor alpha (TNF-α) inhibitors are addressed.</description><identifier>ISSN: 0026-9298</identifier><identifier>PMID: 37143470</identifier><language>ger</language><publisher>Germany</publisher><ispartof>Monatsschrift Kinderheilkunde, 2023, Vol.171 (5), p.420</ispartof><rights>The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2023.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37143470$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hamm, Henning</creatorcontrib><creatorcontrib>Höger, Peter H</creatorcontrib><title>Psoriasis in children and adolescents</title><title>Monatsschrift Kinderheilkunde</title><addtitle>Monatsschr Kinderheilkd</addtitle><description>Psoriasis is nowadays regarded as a multifactorial, inflammatory, immune-mediated systemic condition with predominant involvement of the skin. It starts in about one third of cases in childhood and adolescence and is often accompanied by marked impairment of the quality of life of sufferers and their parents. Aside from genetic disposition, trigger factors such as streptococcal infections are notably involved in manifestation and in exacerbations. The harmful role of comorbidities even in the young, particularly of obesity, has been well documented. Treatment options have considerably improved following the approval of five biologic agents in childhood but are still insufficiently used. The present article gives a short overview of current knowledge and the recommendations of the updated German guideline. Besides frequent types, unusual presentations such as pustular psoriasis, psoriasis dermatitis, and paradoxical psoriasis induced by tumor necrosis factor alpha (TNF-α) inhibitors are addressed.</description><issn>0026-9298</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpjYeA0MDAy07U0srTgYOAqLs4yMDAwNDEyZGfgMDY3NDE2MTfgZFANKM4vykwszixWyMxTSM7IzEkpSs1TSMxLUUhMyc9JLU5OzSsp5mFgTUvMKU7lhdLcDHJuriHOHroFpUm5qSnxBUWZuYlFlfEwc40JKgAA1Kcsbw</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Hamm, Henning</creator><creator>Höger, Peter H</creator><scope>NPM</scope></search><sort><creationdate>2023</creationdate><title>Psoriasis in children and adolescents</title><author>Hamm, Henning ; Höger, Peter H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_371434703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ger</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamm, Henning</creatorcontrib><creatorcontrib>Höger, Peter H</creatorcontrib><collection>PubMed</collection><jtitle>Monatsschrift Kinderheilkunde</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamm, Henning</au><au>Höger, Peter H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psoriasis in children and adolescents</atitle><jtitle>Monatsschrift Kinderheilkunde</jtitle><addtitle>Monatsschr Kinderheilkd</addtitle><date>2023</date><risdate>2023</risdate><volume>171</volume><issue>5</issue><spage>420</spage><pages>420-</pages><issn>0026-9298</issn><abstract>Psoriasis is nowadays regarded as a multifactorial, inflammatory, immune-mediated systemic condition with predominant involvement of the skin. It starts in about one third of cases in childhood and adolescence and is often accompanied by marked impairment of the quality of life of sufferers and their parents. Aside from genetic disposition, trigger factors such as streptococcal infections are notably involved in manifestation and in exacerbations. The harmful role of comorbidities even in the young, particularly of obesity, has been well documented. Treatment options have considerably improved following the approval of five biologic agents in childhood but are still insufficiently used. The present article gives a short overview of current knowledge and the recommendations of the updated German guideline. Besides frequent types, unusual presentations such as pustular psoriasis, psoriasis dermatitis, and paradoxical psoriasis induced by tumor necrosis factor alpha (TNF-α) inhibitors are addressed.</abstract><cop>Germany</cop><pmid>37143470</pmid></addata></record>
fulltext fulltext
identifier ISSN: 0026-9298
ispartof Monatsschrift Kinderheilkunde, 2023, Vol.171 (5), p.420
issn 0026-9298
language ger
recordid cdi_pubmed_primary_37143470
source SpringerLink Journals - AutoHoldings
title Psoriasis in children and adolescents
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T07%3A50%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psoriasis%20in%20children%20and%20adolescents&rft.jtitle=Monatsschrift%20Kinderheilkunde&rft.au=Hamm,%20Henning&rft.date=2023&rft.volume=171&rft.issue=5&rft.spage=420&rft.pages=420-&rft.issn=0026-9298&rft_id=info:doi/&rft_dat=%3Cpubmed%3E37143470%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37143470&rfr_iscdi=true